|
gptkbp:instanceOf
|
gptkb:clinical_trial
|
|
gptkbp:ageRange
|
18 Years and older
|
|
gptkbp:clinicalTrialPhase
|
Phase 3
|
|
gptkbp:clinicalTrialsGovURL
|
https://clinicaltrials.gov/ct2/show/NCT00530894
|
|
gptkbp:completedIn
|
December 2010
|
|
gptkbp:conditionStudied
|
gptkb:Rheumatoid_Arthritis
|
|
gptkbp:enrollment
|
424
|
|
gptkbp:gender
|
All
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
NCT00530894
|
|
gptkbp:intervention
|
gptkb:Methotrexate
gptkb:Abatacept
|
|
gptkbp:location
|
gptkb:Argentina
gptkb:Brazil
gptkb:Canada
gptkb:Mexico
gptkb:Peru
gptkb:Poland
gptkb:Russia
gptkb:Ukraine
gptkb:United_Kingdom
gptkb:United_States
|
|
gptkbp:officialName
|
A Study to Evaluate the Efficacy and Safety of Abatacept or Placebo in Combination With Methotrexate in Subjects With Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Alone
|
|
gptkbp:result
|
Proportion of patients with ACR20 response at 6 months
|
|
gptkbp:sponsor
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:startDate
|
September 2007
|
|
gptkbp:studyType
|
Interventional
|
|
gptkbp:bfsParent
|
gptkb:PARTNER_trial
|
|
gptkbp:bfsLayer
|
8
|